mAb lead optimization
Have a lead antibody, but need humanization or improvement of
affinity or function?
Why Leading Biotechs Choose Abwiz Bio
Founded 2012 · PhD-led scientific team · patented WizAmp™ library construction (US Pat. 9,890,414)
1,338×
Affinity Improvement
2.8×
More Potent Than Infliximab
15/15
Humanization Success
25
Peer-Reviewed Publications
Featured case study
We made infliximab more potent and more developable — and published the step that did not work first time
Humanized onto human germline frameworks, matured with STEM™, then re-engineered by targeted CDR substitution once developability profiling exposed a self-association liability that maturation alone had not removed.
2.8×
more potent than infliximab
4.8×
more potent than adalimumab
19.33 → −1.67
AC-SINS Δλmax (nm)
>1800×
faster off-rate at pH 5.8
Read the case study → See all case studies →
Free 30-minute call with the PhD scientist who would run the work · Initial feasibility assessment within two business days · NDA available before you disclose your target Talk to a scientist →
Abwiz Bio Therapeutic
Antibody Development Plan
Accelerate the development of therapeutic lead candidates with our end-to-end solutions. Every step of our process is fully optimized and tailored to deliver exactly what you need.
STEP 1
Immunization
STEP 2
Library
Construction
WizAmp™
STEP 3
Panning &
Screening
STEP 4
Recombinant
IgG production
STEP 5
Humanization
STEP 6
Affinity Maturation
and Optimization
Stem™